Protalix BioTherapeutics PEG Ratio

The latest PEG ratio for PLX is -2.02. That is below the Healthcare sector average of 11.64. Investors often review this figure alongside Protalix BioTherapeutics's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, PLX currently prints -2.02 for PEG ratio, while the sector average sits near 11.64. That is roughly 117.4% below the sector mean. Large gaps often invite a closer look at Protalix BioTherapeutics's growth, margins, and balance sheet.

A PEG ratio of -2.02 for Protalix BioTherapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (11.64) and with PLX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting PLX's PEG ratio (-2.02), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Protalix BioTherapeutics's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.